ENABLE-2: Open call for antibacterial development programs
The Swedish Research Council and the National Research Programme on Antibiotic Resistance have been commissioned by the Swedish Government to support the ENABLE-2 platform. The platform is open to Swedish academia but also to SMEs through the support from Vinnova. ENABLE-2 is an important contribution to support the global development pipeline of new antibacterials.
The ENABLE-2 platform has now been established and will support the development of direct acting systemic antibacterial compounds (potentiator molecules are also in scope, e.g. β-lactamase inhibitors). The goal of ENABLE-2 will be to develop Hits up to a level of advancement where they can successfully graduate to later stage initiatives (e.g., CARB-X, GARDP, REPAIR Impact Fund) or to out-licensing. Pathogens in scope for the Open Call are E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus and E. faecium (ESKAPE pathogens). The platform will be able to run three programmes in parallel.
This initial call is open exclusively to Swedish research groups, including both academics and SMEs. Please visit the website for more information about the platform and instructions on how to submit an Expression of Interest. The Open Call will be open between October 4 and October 31, 2021.
Next Drug Discovery Seminar: Oct 28th
Topic: Targeting the oncogenic TGFβ signaling pathway in cancer to inhibit invasion and metastasis.
Speaker: prof Maréne Landström, Dept. Medical Biosciences, Umeå University
We are currently looking to recruit a new Head of Unit for our Human Antibody Therapeutics (HAT) unit. The HAT team is an established and high-performing unit with a staff of six senior researchers, scientifically supported by three platform scientific directors (professor level). The unit has laboratories at both SciLifeLab campus in Stockholm, and at Medicon Village in Lund.
Interested? Read more here.
Recent developments at the DDDP
With its mission to support researchers in developing prototypes for new drugs, the DDD platform is focused on providing state-of-the-art drug discovery technologies to scientists across the country. During the last couple of years, the platform has developed DNA-coded chemical libraries that make it easier to find relevant starting points for small molecule drug discovery. In 2020, the platform launched its third library, containing over one million unique DNA-coded drug-like substances. Currently used for COVID-19 projects, the library will be made available for academic researchers nationwide in 2021.
The platform also recently established a new methodology for developing PROTACs
® (Proteolysis targeting chimera), a new kind of drug which breaks down target proteins instead of inhibiting their functions. In 2020, the platform’s researchers – in close collaboration with scientists at Karolinska Institutet, Uppsala University and Recipharm AB – showed the first functional degrader to be produced in Swedish academia. Now, the aim is to make this technology available to users in early 2022.
In 2020, the activities at the platform were in many ways affected by the corona pandemic, but despite restrictions, the platform managed to carry out most of its operations as planned. During the year, it added three new academic projects to its portfolio, and carried out two successful exits; one of which, a project on developing a new kind of cell therapy (CAR-T) for glioblastoma, was advanced into a private company that will continue its development.
The platform also launched two research projects on COVID-19 – one aiming to identify inhibitors of a viral protease essential to the growth of the virus, and one where antibodies with high-binding strength to the virus surface protein have been identified.
The DDD platform has until recently focused on small molecules and protein drugs; a recent addition is oligonucleotides. Oligonucleotide drugs have a potentially faster development compared to other drug types. The OligoNova Hub is based in Gothenburg and will become part of SciLifeLab’s DDD platform.
”This endeavour enables the DDD platform to take on new kinds of projects for diseases with unmet medical needs, and focus on different therapies. It also creates several potential synergies, for instance, a possibility to combine DDD’s unique antibody expertise with oligonucleotide drugs to facilitate delivery to the correct cell type”, says Kristian Sandberg, Co-Director of the platform.
“The OligoNova Hub will establish a vibrant center based on scientific excellence for these new medicines, creating a unique opportunity for SciLifeLab to work on new drugs together with the life science community in Sweden. We look forward to working with the Wallenberg Centre for Molecular and Translational Medicine, to make these technologies available to researchers across the country”, he continues.
SciLifeLab DDDP and Testa Center collaborate on scaling up antibody production
28 June 2021
After more than four years of collaborative research, SciLifeLab Group leader Sara Mangsbo (Uppsala University) is ready to leave the SciLifeLab Drug Discovery and Development Platform (DDD) with her innovative immunotherapeutic cancer vaccine delivery platform. Read the full article here.
Sara Mangsbo receiving the data from SciLifeLab DDDP at the project exit event in June 2021. Photo: Mikael Wallerstedt
2 March 2021
DDDP adds a new therapeutic approach to the platform’s repertoire: oligonucleotide drugs.
Read more about the new OligoNova hub.
Activation of potassium channels
“SciLifeLab Drug Discovery & Development project owner and SciLifeLab board member Professor Fredrik Elinder was interviewed in the ionchannellibrary. He outlines the challenge of undertaking and funding drug discovery efforts in academia, the need for high-throughput ion channel measurements, and ultramarathons – all in one place.
What do we offer?
The SciLifeLab Drug Discovery and Development platform (DDD) offers integrated drug discovery efforts to the Swedish academic research community. We offer industry standard infrastructure, expertise, and strategic support for technology development or to help progress projects towards a preclinical proof-of-concept. We work with small molecules, human antibodies, and new modality therapeutics. There are three ways to interact with us:
|Drug development project||Access to resources/instruments/|
technologies at DDD
|Access to spare resources/|
instruments at DDD
E-mail us to start discussing your project
Units of the DDD Platform
Services are offered in the following areas:
Importantly, the researcher/customer retains all rights and ownership during this process.
For the latest updates, please follow us on LinkedIn.
“We couldn’t have done this project without SciLifeLab. To begin with, we didn’t even know which things we didn’t know, so to speak. Nor did we have the funds to be able to do it ourselves. The vast competence of the DDD platform scientists has been invaluable to us.”
Olle Hernell (Umeå University)
“To have access to the expertise and techniques provided by the DDD was critical for us in order to be able to advance our research.”
Tina Sarén (Uppsala University)
We are currently running 19 drug discovery projects at the DDD platform: antibody, small molecule, and new modality projects. The DDD Platform strives to stay up to date with current drug discovery techniques used in the pharmaceutical industry.
Small molecule projects
Recent project exits
|Year||Principal Investigator||Affiliation||Therapeutic area||Project Type|
|2021||Sara Mangsbo||Uppsala University||Oncology||New Modalities|
|2020||Mattias Hallberg||Uppsala University||Neuroscience||Small Molecule|
|2020||Magnus Essand||Uppsala University||Oncology||New Modalities|
|2019||Susanne Lindqvist||Umeå University||Autoimmune Diseases||Antibody|
|2019||Sonia Lain||Karolinska Institute||Oncology||Small Molecule|
|2018||Margit Mahlapuu||Gothenburg University||Metabolic Disorders||Small Molecule|
|2018||Per Almqvist||Karolinska Institute||Neuroscience||New Modalities|
|2017||Maria Eriksdotter||Karolinska Institute||Neuroscience||Small Molecule|
|2016||Mårten Fryknäs||Uppsala University||Oncology||Small Molecule|
|2016||Johan Flygare||Linköping University||Blood Disorders||Small Molecule|
|2016||Thomas Helleday||Karolinska Institute||Oncology||Small Molecule|
The Drug Discovery and Development (DDD) Platform at SciLifeLab has entered into a research collaboration with the Swedish drug development company Medivir AB. The aim is to find inhibitors of the main protease of SARS CoV-2, an essential non-structural protein known as Mpro, which is required for virus replication. To identify putative inhibitors and evaluate active compounds as potential drug development candidates, the DDD platform will mine a unique protease-targeted compound library, developed at Medivir. Data for up to 100 top-inhibitors will be published by SciLifeLab online, openly available for drug development efforts focused on combating COVID-19.
UppTalk weekly recently (24 November 2020) published a video with Jens Carlsson from Uppsala University, where he talks about our collaboration project around SARS CoV-2 main protease drug discovery, and how molecular dynamics simulations can accelerate drug discovery. The video is in Swedish.
The SciLifeLab Symposium: “Accelerating the process from basic drug discovery to clinical trial for Covid-19” from Dec 1, 2020, is now available on YouTube. This Covid19-focused symposium will bring together scientists pushing the boundaries of drug discovery to find remedies for ongoing Covid-19 pandemic and future epidemics. We will hear about how basic research in drug discovery has been taken to clinical practice, get examples of ongoing clinical trials, and increase our understanding of suitable animal models. The event will include a panel discussion with presenters about the current challenges to find a drug for Covid-19.